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Introduction: Nicotine, the major component among the 4000 iden-
tified chemicals in cigarette smoke, binds to nicotinic acetylcholine 
receptors (nAChRs) on non–small-cell lung cancer (NSCLC) cells 
and regulates cellular proliferation by activating mitogen-activated 
protein kinases [AQ: MAPK has been expanded to mitogen-activated 
protein kinases. Please approve.]and PI3K/Akt pathways. In patients 
with smoking-related lung cancer who continue smoking, the anti-
cancer effect of epidermal growth factor receptor tyrosine kinase 
inhibitor (EGFR-TKI) is weaker than that in nonsmokers; however, 
the precise reason for this difference remains unclear. We investi-
gated the role of α1 nAChR subunit in this phenomenon.
Methods: We screened for α1 nAChR mRNA in three NSCLC cell 
lines and analyzed the protein in resected primary NSCLC tissues. 
We used Western blot and RNA interference (siRNA) methodology 
to confirm the results.
Results: We determined that α1 nAChR plays an essential role in 
nicotine-induced cell signaling and nicotine-induced resistance to 
EGFR-TKI. In addition, we showed that silencing of α1 nAChR 
subunit in NSCLC may suppress the nicotine-induced resistance to 
EGFR-TKI.
Conclusions: These results further implicate nicotine in lung car-
cinogenesis, and suggest that α1 nAChR may be a biomarker for 
EGFR-TKI treatment and also a personalizing target molecule for 
patients with smoking-related lung cancer.
Key Words: Nicotinic acetylcholine receptors, Non–small-cell lung 
cancer, Nicotine, Epidermal growth factor receptor tyrosine kinase 
inhibitor, Targeting therapy.
(J Thorac Oncol. 2013;8: 719-725)
Cigarette smoking is one of the major risk factors associ-ated with non–small-cell lung cancer (NSCLC), which 
accounts for 80% of all lung cancers.1–4 Nicotine, the main 
psychoactive component of cigarette smoke,5 can induce cell 
proliferation, angiogenesis, and resistance to apoptosis,6–9 and 
may also facilitate the development of lung cancer by sus-
tained activation of growth-promoting pathways.10–13 These 
effects of nicotine are mediated by nicotinic acetylcholine 
receptors (nAChRs) that are widely expressed in the lung as 
well as the brain and neuromuscular junctions.5,10,13–15 Nicotine 
also reduces the effectiveness of cancer chemotherapy14,16,17; 
however, the mechanism by which this occurs remains unclear.
nAChRs are either homopentamers or heteropentamers 
consisting of 10 α-subunits (α1–α10), four non–α-subunits β 
(β1–β4), γ, δ, and ε, and are classified into neuronal and mus-
cle forms.5,18 Although the combinations of nAChRs have not 
been completely characterized, it is possible that each subtype 
has distinct pharmacologic properties.19 In addition, nAChRs 
stimulate intracellular signaling pathways in a cell type–spe-
cific manner, thus cell type–specific oncogenesis occurs in 
response to different subunits of nAChRs.13,19 Furthermore, 
significant smoking-dependent declines in expression of α1, 
α5, and α7 nAChR have been reported.13,19 These nAChR sub-
unit genes could be playing roles in nicotine-induced lung can-
cer. Among the subunit genes, α7 nAChR is well studied14,20,21; 
however, little is known about the others. Further evaluation of 
the functional roles played by these nAChR subunit genes in 
nicotine exposure and lung carcinogenesis is needed.
NSCLC is characterized by its poor prognosis and 
resistance to anticancer drugs.22 Now, more than ever, 
clinicians and NSCLC patients are struggling to optimize 
treatments. Although clinical trials have revealed epidermal 
growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) as the most promising therapeutic agent (e.g., erlotinib, 
gefitinib) in NSCLC,23,24 there are still clinical questions to 
be addressed. Recently, smoking (nicotine) exposure has been 
shown to have a negative effect on EGFR-TKI therapy in lung 
cancers,25 although the mechanisms that contribute to the drug 
resistance remain unknown. It has been reported that exposure 
to nicotine increases EGFR expression in lung cells by 
activating survival pathways.10,13,26,27 In addition, differential 
expression of nAChR subunits have been observed between 
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smokers and nonsmokers.19 Therefore, we hypothesized that 
interaction between nicotine and nAChRs may contribute 
to the process that generates resistance against EGFR-TKI 
treatment.
In this study, we focused on the functionality of the 
muscle-type α1 nAChR subunit. We examined the expres-
sion of α1 nAChR mRNA and protein in human NSCLC cell 
lines and human NSCLC tissues. We also analyzed the role 
of nicotine in activations of ERK and Akt (Ser-473) pathways 
through the α1 nAChR in PC9 cells. Finally, we studied the 
ability of nicotine-α1 nAChR signaling to protect NSCLC 
cells from EGFR-TKI treatment.
MATERIALS AND METHODS
Cell Culture
NSCLC cell lines (A549, H2122, and PC9), HEK293, 
and BEAS 2B cells were purchased from American Type 
Culture Collection (Manassas, VA). Cells were cultured in 
Dulbecco’s Modified Eagle Medium or Roswell Park Memorial 
Institute media supplemented with 10% fetal bovine serum 
and incubated at 37°C in 5% carbon dioxide.
Real-Time Reverse Transcription Polymerase 
Chain Reaction of α1 nAChR
Total RNA was isolated with an RNeasy Mini kit from 
Qiagen (Valencia, CA), and RNA (1μg) was reverse-transcribed 
to generate cDNA with PrimeScript RT reagent kit (Perfect 
Real Time, Takara, Japan) according to the manufacturer’s pro-
tocol. The primers and conditions for real-time reverse-tran-
scriptase polymerase chain reaction (RT-PCR) were described 
elsewhere.19 The relative quantitation value for α1 nAChR 
gene compared with the calibrator was expressed as 2−(Ct−Cc) (Ct 
and Cc are the mean threshold cycle differences after normal-
izing to 18S). A 10-μl aliquot of each reaction was analyzed 
on 2% agarose gels. glyceraldehyde-3-phosphate dehydroge-
nase (GADPH) (5′-ACCTACCAAATATGATGACATCA-3′, 
5′-CGCTGTTGAAGTCAGAGGA-3′) was used as a positive 
control for RNA integrity.
Western Blot Analysis
A549, PC9, and H2122 cells were rinsed with ice-cold 
phosphate-buffered saline and scraped into lysis buffer with 
protease inhibitors and phosphatase inhibitor. Protein was 
quantitated with the BCA assay (Thermo Scientific, Pierce). 
Whole-cell lysates were used for Western blot analysis. In 
brief, cell lysates adjusted for protein concentration were sepa-
rated on 10% sodium dodecyl sulfate polyacrylamide gels and 
electrotransferred to polyvinylidene fluoride membranes. The 
transferred membranes were blocked with 3% nonfat milk and 
incubated with appropriate primary antibody (Sigma-Aldrich, 
St. Louis, MO) overnight at 4°C. Membranes were then washed 
briefly and incubated with horseradish peroxidase-conjugated 
secondary antibody (Cell Signaling Inc., Beverly, MA).
Immunohistochemistry for α1 nAChR
For immunohistochemistry (IHC), 43 paraffin-embed-
ded lung cancer samples were obtained from the Department 
of Pathology in Kyushu University Hospital. The patients’ 
characteristics are summarized in Table 1. Clinicopathological 
factors, including sex, smoking history, and tumor type were 
evaluated. The samples included 32 adenocarcinomas, seven 
squamous cell carcinomas, two large-cell carcinomas, and two 
small-cell carcinomas. Formalin-fixed and paraffin-embedded 
tissue blocks were cut into 4-μm sections. The slides were 
deparaffinized and hydrated and then pretreated for micro-
waving. Endogenous peroxidase was quenched with metha-
nol/peroxide. The slides were blocked with rabbit serum, 
incubated with primary α1 nAChR antibody overnight (Salk 
Institute by Sigma), and then incubated with secondary anti-
body (Dako). Immunodetection was performed with an avi-
din-biotin horseradish peroxidase method and visualized with 
3,3 ′-diaminobenzidine (DAB) as the chromogen. The slides 
were then counterstained with hematoxylin.
Scoring of α1 nAChR Expression
Immunoreactivity was scored according to the per-
centage (P) of tumor cells showing characteristic membrane 
staining (0, undetectable; level 1, few; level 2, <10%; level 3, 
10%–50%; and level 4, >50%) and the intensity (I) of stain-
ing (1, weak; 2, moderate; and 3, strong). Expression of α1 
nAChR in each section was scored by multiplying P by I, the 
so-called quick score (Q) (Q = P × I; maximum = 12). We clas-
sified staining as low-positive (Q ≤ 6; n = 16, [including nega-
tive Q = 0]) versus high-positive (Q > 6; n = 27). Assessments 
were made by two independent observers blinded to histologic 
diagnoses. The correlation between clinicopathological fac-
tors was analyzed using ÷2 tests.
RNA Interference
Chemically synthesized double-stranded siRNA spe-
cific for nAChR α1 was purchased from Dharmacon Research 
(Thermo Fisher Scientific, Lafayette, CO). The siRNA was trans-
fected (100 nmol/L) with DharmaFECT reagents according to 
the manufacturer’s instructions. A nontargeting (NT) siRNA 
sequence (Dharmacon Research) was used as nonspecific control.
Cell Survival after EGFR-TKI Treatment
Intact PC9 cells and PC9 cells pretreated with nicotine 
(Sigma) were seeded at a density of 5,000 cells per well in a 96-well 
plate in complete medium overnight. Cells were treated with vari-
ous concentrations of EGFR TKI (Calbiochem EMD Biosciences, 
La Jolla, CA) for 48 hours, and then 20 µl of 3-(4,5-dimethylthia-
zol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tet-
razolium, inner salt (MTS) reagent (Promega, Madison, WI) was 
added per well for 1 hour. Survival was determined by comparison 
of the absorbance at 490 nm with that of the control.
Statistical Analysis
Data are presented as the mean ± SEM for three 
independent experiments. The ÷2 tests were used to compare 
two groups, and one-way analysis of variance was used to 
analyze data among groups for significant difference. A p value 
less than 0.05 indicated a statistically significant difference. 
JMP version 9 (SAS Institute Inc., Cary, NC) software was 
used for all analyses.
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RESULTS
Expression of the α1 nAChR Subunit in NSCLC 
Cell Lines and in Human NSCLC Tissues
Three NSCLC cell lines (A549, PC9, and H2122) were 
examined for expression of α1 nAChR subunit mRNA by RT 
PCR. BEAS 2B cells were used as a positive control,13,15 and 
GAPDH was included in each panel as a reference. As shown 
in Figure 1A, all three cell lines expressed α1 nAChR mRNA. 
Expression of the receptor proteins in the four cell lines was 
confirmed by Western blot with HEK293 cells as the negative 
control.3 All four cell lines expressed detectable levels of the 
α1 nAChR subunit, as shown in Figure 1B.
We also examined paraffin-embedded specimens of 
human NSCLC tumors for expression of α1 subunit by IHC. 
Our series of NSCLC types included 32 adenocarcinomas, 
seven squamous cell carcinomas, two large-cell carcinomas, 
and two small-cell carcinomas. Although a certain level of 
expression of α1 nAChR was shown in almost all types of 
lung cancer, statistical analysis showed that the adenocarci-
noma tissues were stained more strongly than the nonadeno-
carcinoma tissues (Table 1). Representative photographs of 
positive immunostaining for each histological type of lung 
cancer are shown in Figure 2. The results suggested that the 
α1 nAChR might have a function in lung tumors, especially 
in adenocarcinoma.
Roles of the α1 nAChR Subunit in Nicotine-
Induced Cell-Signaling Pathways of NSCLCs
These studies led to the realization that the α1 nAChR 
may have functional roles in NSCLC cells. Indeed, given the 
fact that nicotine could induce cell proliferation, angiogenesis, 
and growth of tumors,10–13,28 we next examined the ERK1/2, Akt 
(Ser-473), and STAT3 pathways induced by nicotine in PC9 
cells. In Western blot analysis, we found that phosphorylated 
ERK1/2 and PI3K/ Akt (Ser-473) increased in a time-
dependent manner after treatment with nicotine (Fig. 3A). 
In contrast, phosphorylated STAT3 was not detected at all. To 
further determine whether α1 nAChR subunit was directly 
involved in the ERK1/2 and Akt (Ser-473) pathways, PC9 cells 
were transfected with siRNA targeting α1 nAChR (si-α1) or 
NT siRNA (si-NT). Markedly down-regulated expression of 
phosphorylated Akt (Ser-473) and phosphorylated ERK1/2 
protein was seen by Western blot (Fig. 3B). Taken together, 
these results suggested that α1 nAChR contributed, at least 
in part, to nicotine-induced activation of the ERK1/2 and Akt 
(Ser-473) pathways in PC9 cells.
Effects of the α1 nAChR Subunit in Nicotine-
Induced EGFR Signaling Pathways of NSCLCs
The experiments with siRNA targeting α1 nAChR 
showed that phosphorylation of Akt (Ser-473) and ERK1/2 
can be partially blocked in PC9 cells. EGFR has been reported 
to activate the same downstream pathways as α1 nAChR.26 
Considering the cross-talk between downstream signaling by 
EGFR and α1 nAChR, it is possible that nicotine activates 
EGFR through the activation of ERK1/2 and PI3K/Akt (Ser-
473). In the studies that followed, we observed that nicotine 
caused time-dependent phosphorylation of EGFR in PC9 
cells (Fig. 3C), and that the knockdown of α1 nAChR expres-
sion by siRNA could reduce the protein levels of both EGFR 
and phosphorylated EGFR (Fig. 3D). Gene silencing of α1 
nAChR by siRNA was validated by real-time RT PCR (Fig. 
4A, B). These results suggest that α1 nAChR might act as an 
upstream regulator of the EGFR pathway in PC9 cells.
TABLE 1.  Association between α1 nAChR Expression and 
Clinicopathological Factors in NSCLC
Factors
Total 
Patients 
N = 43
α1 nAChR- 
High Positive 
n = 27
α1 nAChR-Low 
Positive  
n = 16 p
Sex
 Male 25 18 7 0.2035
 Female 18 9 9
Smoking history
 Smoker 27 13 14 0.0206
 Never smoked 16 14 2
Tissue type
 Adenocarcinoma 32 24 8 0.0138
 Nonadenocarcinomaa 11 3 8
aSeven squamous cell carcinomas; two large-cell carcinomas; two small-cell carcinomas.
nAChR, nicotinic acetylcholine receptor.
FIGURE 1. A, NSCLC cell lines express nAChR mRNA and 
protein. Detection of reverse-transcriptase polymerase chain 
reaction products for α1 nAChR subunits in A549, H2122, 
and PC9 cell lines. The BEAS 2B cell line was a positive control. 
Products were sequenced and in each case confirmed to be 
the expected authentic sequence for each subunit. M, 100 bp 
molecular marker with the brightest band at 600 bp. B, Western 
blot results for α1 nAChR subunits. NSCLC cell lines express 
nAChR protein. BEAS 2B cell line or HEK293 cell line served as 
the positive or negative control, respectively. nAChR, nicotine 
acetylcholine receptors; NSCLC, non–small-cell lung cancer.
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Nicotine-Induced Resistance to EGFR-TKI
Nicotine-induced activation of pathways related to pro-
liferation (PI3K/Akt, ERK1/2, and EGFR) suggested that 
exposure to nicotine might protect cancer cells against the 
cytotoxic effects of EGFR-TKI. Therefore, we investigated 
whether nicotine exposure caused resistance to EGFR-TKI 
in PC9 cells (Fig. 5A). EGFR-TKI had a dosage-dependent 
killing effect in PC9 cells as shown in Figure 5A (open bar). 
However, PC9 cells pretreated with nicotine were not killed 
as effectively by EGFR-TKI. When PC9 cells were pretreated 
with nicotine for 24 hours, larger numbers survived treatment 
with 5 or 10 µmol of EGFR-TKI as compared with unexposed 
PC9 cells. When PC9 cells were pretreated with nicotine for 
1 month, the resistance against EGFR-TKI was clear at a con-
centration of EGFR-TKI as high as 20 µmol. Finally, restora-
tion of sensitivity to EGFR-TKI was examined by α1 nAChR 
knockdown in nicotine-exposed PC9 cells. PC9 cells were 
incubated in the presence or absence of 1 µmol of nicotine for 
1 month,19 then transfected with siRNA α1 or NT siRNA for 
72 hours. As shown in Figure 5B, siRNA against α1 nAChR 
decreased the resistance to EGFR-TKI induced by nicotine. In 
contrast, the resistance persisted in cells stimulated by nico-
tine and transfected with NT siRNA. These results suggested 
that the enhanced resistance to EGFR-TKI in PC9 cells stim-
ulated by long-term nicotine exposure was, at least in part, 
dependent on α1 nAChR expression.
DISCUSSION
More than one billion people around the world smoke, 
and cigarette smoking and second-hand smoking account for 
nearly 90% of lung cancer deaths.29 Studies in recent years 
raise the possibility that exposure to nicotine might lead to 
increased risk of lung cancer30; however, the detailed molecular 
mechanisms remain largely unknown. The fact that nicotine 
promotes lung cancer by activating different nAChR subunits, 
thus leading to the activation of several pathways,10,12,13 gives 
reason to believe that the nAChR family may play important 
roles in lung tumorigenesis.
In the present study, expressions of α1 nAChR mRNA 
and protein were determined in NSCLC cell lines. The results 
also proved to be applicable to human NSCLC by analysis of 
lung cancer human tissues with IHC. Consistent with previous 
reports,10,12,19 all these data suggested that α1 nAChR is likely 
to be involved in the smoking-related pathogenesis of NSCLC.
In accordance with the roles of nicotine in multiple sig-
naling pathways of NSCLC,10–13 we found that exposure to nic-
otine stimulated phosphorylation of ERK1/2 and Akt (Ser-473) 
in a time-dependent manner. The phosphorylation was evident 
within 5 minutes and reached a peak within 30 minutes, sug-
gesting that the triggering of these pathways could play a role 
in the early development of nicotine-induced NSCLC (failure 
of detection of STAT3 phosphorylation may be because of 
the inappropriate cell line).28 Because the nicotine-activated 
adenocarcinoma
squamous cell carcinoma
large cell carcinoma
small cell carcinoma
A C
DB
FIGURE 2.  Representative photographs of tissue microarrays showing that non–small-cell lung cancer tissue expressed α1 
nicotine acetylcholine receptors. Dark-brown staining was indicative of the presence of α1 protein, and tissue was counter-
stained to indicate nuclei with dark-blue staining. A, adenocarcinoma ×400; (B), squamous cell carcinoma ×400; (C), large-cell 
carcinoma ×400; and (D), small-cell carcinoma ×400.
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signaling pathways were also thought to be involved with 
EGFR,26,31,32 cross-talk between EGFR and nAChR was pro-
posed. In support of this hypothesis, we found in our present 
study that nicotine caused phosphorylation of EGFR in a time-
dependent way. Therefore, we next attempted to identify the 
specific nAChR subunit responsible for these effects. Although 
A B
C D
FIGURE 3. A, Induction of Erk, Akt (Ser-473) and STAT3 phosphorylation by nicotine. PC9 cells were serum-starved for 24 
hours then incubated with 10 µM of nicotine for the number of times indicated (upper panel). Western blot analysis was used 
to reveal the time-dependent phosphorylation of ERK and Akt (Ser-473); (B) Induction of Erk and Akt (Ser-473) phosphorylation 
was dependent on α1 nAChR. PC9 cells were transfected with siRNA against α1 nAChR subunit (si-α1) or NT siRNA for 72 hours. 
Western blot analysis revealed the difference in phosphorylated levels of ERK1/2 (p-ERK1/2) and Akt (p-Akt) between cells treated 
with siRNA α1 and NT; (C) Induction of EFGR phosphorylation by nicotine. PC9 cells were serum-starved for 24 hours then incu-
bated with 10 µM of nicotine for the number of times indicated (upper panel). Western blot analysis shows the EGFR and p-EGFR 
protein levels; (D) Role of α1 nAChR subunit in the EFGR signaling pathway. PC9 cells were transfected with siRNA against the α1 
nAChR subunits (si-α1) or NT siRNA for 72 hours. Western blot analysis shows EGFR and p-EGFR protein levels. EFGR, epidermal 
growth factor receptor; ERK, extracellular signal-regulated kinase; nAChR, nicotinic acetylcholine receptor; NT, nontargeting.
FIGURE 4. A, Gene silencing of 
α1 nAChR was validated by reverse 
transcription PCR in PC9 cells. 
α1 nAChR mRNA expression was 
knocked down by siRNA; (B) The 
relative levels of α1 nAChR mRNA 
measured by real-time-PCR in con-
trol NT and α1 nAChR knockdown 
(si-α1) PC9 cells. Data are presented 
as mean ± standard error mean of 
three independent experiments 
carried out in triplicate. *p < 0.05. 
nAChR, nicotinic acetylcholine 
receptor; NT, nontargeting; PCR, 
polymerase chain reaction.
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several functional subunits of nAChRs have been reported 
recently,20,33 our IHC results suggest the possibility that nicotine 
could act through a pathway from α1 nAChR to EGFR as well.
Consistent with these findings, our blocking experi-
ments (siRNA) and Western blot analysis proved that α1 
subunit was responsible for EGFR release, and that siRNA 
down-regulated phosphorylation of EGFR by reducing phos-
pho-ERK and phospho-Akt (Ser-473). Thus, we provide the 
following new information about nicotine-induced signaling 
pathways in PC9 NSCLC cells. First, nicotine was suggested 
as inducing EGFR-signaling pathways. Second, nicotine 
increased expression and phosphorylation of EGFR, which 
was coupled with increased ERK and AKT phosphorylation. 
These findings suggest that in PC9 cells, nicotine-stimulated 
cell proliferation and survival may be partially dependent on 
EGFR signals transmitted through AKT and ERK pathways. 
Third, the phosphorylation of EGFR, ERK, and Akt (Ser-473) 
were down-regulated by treatment with si–α1 nAChR, sug-
gesting that α1 nAChR may act as an upstream regulator of 
the EGFR pathway in PC9 cells and may be responsible for 
mediating the proliferative and apoptotic effects caused by 
nicotine exposure. Here we identified a novel nicotine-stim-
ulated survival signaling pathway mediated by α1 nAChR 
through EGFR phosphorylation.
It has been shown that never-smokers with lung cancer 
are more likely to respond to EGFR-TKI treatment than 
smokers.34 Although one major mediator of responsiveness 
to EGFR-TKI is the mutation status of EGFR that is often 
shown in never-smokers,35 we conjectured that nicotine–α1 
nAChR signaling pathways may contribute to differences 
in responsiveness to EGFR-TKI therapy between never-
smokers and active smokers or exsmokers who use nicotine 
replacement therapy. Our results from the MTS assay showed 
that both short-term (10 µm of nicotine for 1 day) and chronic 
nicotine stimulation (1 µm of nicotine for 1 month) did confer 
protection from EGFR-TKI-induced cytotoxicity in PC9 cells. 
Notably, under conditions of chronic stimulation by nicotine, 
the resistance to EGFR-TKI was significantly abrogated by 
silencing α1 nAChR (siRNA). These observations suggested 
that in addition to nicotine exposure or smoking status, 
continued or chronic exposure to nicotine (usually taken to be 
>10 days of continuous exposure to nicotine)19 increased the 
resistance to EGFR-TKI compared with immediate or short-
term exposure to nicotine; furthermore, the α1 nAChR subunit 
was responsible for mediating the resistance of EGFR-TKI 
induced by chronic nicotine exposure in PC9 cells. Therefore, 
elimination of α1 nAChR subunit or treatment with an α1 
nAChR–specific inhibitor could provide highly tailored 
treatments for smoking NSCLC patients.
In summary, the results of our report, together with pre-
viously published reports suggest that the EGFR system shares 
significant cross-talk with the nAChR system in NSCLC cell 
lines. Our results indicate that the α1 nAChR subunit mediates 
resistance to EGFR-TKI therapy, induced by chronic nicotine 
exposure, through activation of the ERK and Akt (Ser-473) 
pathways. Thus, our findings might provide a mechanistic 
basis for the resistance to EGFR-TKI therapy, observed in 
patients who continue to smoke. A major problem of current 
NSCLC therapy is the fact that this cancer expresses many dif-
ferent signaling pathways. Inhibition of the activities of ERK, 
AKT, or EGFR pathways and other angiogenic regulators are 
therefore, currently targeted therapies that require treatment 
with multiple agents. Given the potential role of α1 muscle-
type nAChR in several of the important pathways, targeted 
inhibition of α1 nAChR might become a novel treatment in 
NSCLC. In addition, the notion that α1 nAChR functions to 
promote lung carcinogenesis raises questions regarding the 
safety and appropriateness of nicotine-replacement therapies. 
Also, as smoking cessation is the most effective way to pre-
vent nicotine-induced EGKR-TKI resistance, the study gives 
us a substantial reason to advocate smoking cessation for the 
cancer patients who smoke.
FIGURE 5. A, Nicotine protects NSCLC cells from cytotoxicity induced by EGFR-TKI. NSCLC PC9 cells were pretreated with 1 
µM of nicotine for 1 month or 10 µM of nicotine for 1 day. Cells were then treated with EGFR-TKI for 48 hours. Cell survival was 
measured with the MTS assay and was expressed as a percentage of the untreated control. The concentrations of EGFR-TKI were 
increased in increments as indicated. Data are presented as mean ± standard error mean of three independent experiments carried 
out in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001. B, α1 nAChR subunit mediated EGFR-TKI resistance induced by long-term 
nicotine exposure. PC9 cells were pretreated with 1µM of nicotine for 1 month, then transfected with siRNA against α1 nAChR 
subunit (si-α1) or nontargeting siRNA NT for 72 hours. Cell survival was measured with the MTS assay and is expressed as a per-
centage of the untreated control. The concentrations of EGFR-TKI were increased in increments as indicated. Data are presented as 
mean ± standard error mean of three independent experiments carried out in triplicate. *p < 0.05; **p < 0.01; ***p < 0.001. EFGR-
TKI, epidermal growth factor receptor tyrosine kinase inhibitor; NSCLC, non–small-cell lung cancer; NT, nontargeting.
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Finally, future exploration of nicotine–α1 nAChR-
induced lung carcinogenesis should address the question of 
whether lung cancer risk is directly influenced by α1 nAChR or 
indirectly influenced by smoking behaviors; the effects of ciga-
rette exposure on the pharmacokinetics involved in the EGFR-
TKI resistance actions36 should also be raised. Moreover, other 
nAChR subunit genes in chronic nicotine exposure warrant fur-
ther evaluation.
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